Applied Therapeutics Inc. (NASDAQ:APLT) Receives $4.13 Consensus Price Target from Brokerages

Shares of Applied Therapeutics Inc. (NASDAQ:APLT) have received an average rating of “Hold” from the six research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.1250.

APLT has been the subject of a number of research reports. Wall Street Zen raised shares of Applied Therapeutics to a “sell” rating in a report on Saturday, July 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Applied Therapeutics in a report on Saturday, September 27th.

Applied Therapeutics Price Performance

Shares of Applied Therapeutics stock opened at $1.14 on Friday. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The firm has a fifty day moving average price of $0.59 and a two-hundred day moving average price of $0.46. The company has a market cap of $164.17 million, a PE ratio of -2.53 and a beta of 2.07.

Applied Therapeutics (NASDAQ:APLT) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. Analysts expect that Applied Therapeutics will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Applied Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. boosted its position in Applied Therapeutics by 91.5% in the first quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company’s stock valued at $5,076,000 after buying an additional 4,959,670 shares in the last quarter. Propel Bio Management LLC boosted its position in Applied Therapeutics by 17.4% in the first quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company’s stock valued at $5,517,000 after buying an additional 1,670,000 shares in the last quarter. AQR Capital Management LLC acquired a new position in Applied Therapeutics in the first quarter valued at about $280,000. Alyeska Investment Group L.P. boosted its position in Applied Therapeutics by 14.8% in the first quarter. Alyeska Investment Group L.P. now owns 3,107,497 shares of the company’s stock valued at $1,519,000 after buying an additional 400,000 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Applied Therapeutics in the first quarter valued at about $137,000. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.